Tapinarof is showing promise in the landscape of dermatological treatment. Adelaide Hebert, MD, FAAD, recently served as an investigator for 2 studies presented at the European Academy of Dermatology and Venereology (EADV) Congress and discussed key points with Raj Chovatiya, MD, PhD.
Read the top 10 takeaways from a recent discussion among experts in the management of plaque psoriasis.
Aesthetic procedures for patients with skin of color necessitate a nuanced approach that prioritizes patient safety and optimal outcomes.
Check out these 5 factors that can significantly impact a dermatologist’s financial plan and should therefore incorporate flexibility and resiliency to structure the plan for long-term success.
Chiesi Global Rare Diseases recently announced the approval of the topical treatment.
Nanette Silverberg, MD, takes a deep dive into the importance of early intervention and gave an overview of topical care for patients of all ages with vitiligo.
Roundtable participants shared 10 different considerations to make for a patient, like this 23-year old woman, with a new environment and lifestyle.
The Society for Immunotherapy of Cancer recently published insights into the management of patients with preexisting autoimmune disease, solid organ transplant recipients, elderly individuals, those living with HIV, pregnant patients, and those with rare noncutaneous subtypes of melanoma.
Lisa Swanson, MD, FAAD, and Robert Casquejo, PA-C, discuss their preferred treatment approach for plaque psoriasis, which includes PDE4 inhibitors such as apremilast and roflumilast.
Click here to answer this week's poll about a recent FDA Complete Response Letter.
Review a rundown of our top articles and resources for patients inspired by National Eczema Awareness Month.
A recent study presents a unique case of sudden-onset vitiligo following the COVID-19 vaccination, along with a systematic review of existing literature to shed light on the potential link between vaccination and vitiligo development.
Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.
At 3 years, V940 plus pembrolizumab reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%.
Keep up with the latest headlines in dermatology from the past week, including a new immuno-dermatology partnership, promising study results from a combined mRNA vaccine and Keytruda for advanced melanoma, and more.
Here is a recap of the drugs and treatments approved to keep in mind for the new year.
ICYMI, this week we had articles about coverage from the Revolutionizing Atopic Dermatitis and Vitiligo virtual conferences, expert insights on AAD's updated AD management guidelines, positive data of axitinib for basal cell carcinoma, and more.
Roflumilast foam 0.3% is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.
The confirmatory phase 3 trial demonstrated significant efficacy of TO-208 versus a placebo.
A poster from the RAD Virtual Conference reviewed the relationship between Black and DHH patients and the shared disparities these populations face.
Adbry (tralokinumab-LDRM) is now the first and only FDA-approved biologic for AD binding to and inhibiting IL-13.
Catch up on coverage from this week's virtual Revolutionizing Atopic Dermatitis and Revolutionizing Vitiligo conferences.
The emergence of JAK inhibitors has shown tremendous promise as a novel therapeutic approach.
David Rosmarin, MD, presented new and upcoming pipeline updates for the treatment of vitiligo at the Revolutionizing Vitiligo Virtual Conference.
Cognizance and certain clues may help dermatologists in recognizing antifungal-resistant dermatophyte infections.
Biolojic’s BD9 is a dual specific antibody that can block both Thymic stromal lymphopoietin and IL-13.
Staying on top of products and ingredients patients are asking about is critical, especially this holiday season as they are considering gifts for loved ones.
52% of adult patients achieved the treat-to-target goal of 1% BSA or less within 3 months of incorporating tapinarof cream into their biologic regimen.
Lesional stability is a necessary requirement for determining the course of treatment for vitiligo.
Study authors hypothesize that a monoclonal blockade of pathogenic T cells may induce expansion of regulatory immune cells subsets or expression of cytokines involved in skin homeostasis.
